Trial · NCT03640949

Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest

NCT03640949, Phase 2, Phase 3, Completed, Lars Wiuff Andersen; results first posted 2022-01-11

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest. Trials, record NCT03640949. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03640949

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest
NCT number: NCT03640949
Status: Completed
Phases: Phase 2, Phase 3
Enrollment: 501 participants, actual
Lead sponsor: Lars Wiuff Andersen
Conditions: Heart Arrest
Interventions: Vasopressin, Arginine, Methylprednisolone, NaCl
First posted: 2018-08-21
Last updated: 2022-03-02
Other registries' IDs: eudract:2017-004773-13
Results first posted: 2022-01-11

Source ClinicalTrials.gov

Registered outcomes12

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Participants With Return of Spontaneous Circulation	During the cardiac arrest, an average of 20 minutes	Return of spontaneous circulation is defined as spontaneous circulation with no further need for chest compressions sustained for at least 20 minutes
Secondary	Number of Participants That Survived 30 Days	At 30 days
Secondary	Number of Participants With a Favorable Neurological Outcome at 30 Days	At 30 days	A favorable neurological outcome will be defined as a cerebral performance category score of 1 or 2. The cerebral performance category score is a 5-point scale assessing neurological/functional outcomes after brain damage with higher scores indicating worse neurological/functional outcomes.
Other	Vasopressor-free Days	7 days	Vasopressor-free days will be defined as the number of days within the first 7 days after the cardiac arrest where the patient is not receiving vasopressors and is alive.
Other	Invasive Ventilation-free Days	7 days	Invasive ventilation-free days will be defined as the number of days within the first 7 days after the cardiac arrest where the patient is not receiving invasive ventilation and is alive.
Other	Sequential Organ Failure Assessment (SOFA) Score at 24, 48 and 72 Hours	24, 48 and 72 hours	The SOFA score is a validated and widely used measure of organ failure assessing the respiratory, nervous, cardiovascular, hepatic, coagulation, and renal systems. We will assess both the cardiovascular sub score as well as the overall SOFA score.
Other	Hospital Disposition	At hospital discharge, up to 1 year	Hospital disposition (e.g. home, rehabilitation, nursing home, hospice) will be defined at the time of discharge from the initial acute care hospital.
Other	Survival	At 90 days, 180 days, and 1 year
Other	Favorable Neurological Outcome	At 90 days, 180 days, and 1 year	A favorable neurological outcome will be defined as a cerebral performance category score of 1 or 2. The cerebral performance category score is a 5-point scale assessing neurological/functional outcomes after brain damage with higher scores indicating worse neurological/functional outcomes.
Other	Modified Rankin Scale (mRS)	At 30 days, 90 days, 180 days, and 1 year	The mRS is a 7-point scale, ranging from 0 (no symptoms) to 6 (dead), assessing the degree of disability and dependence after a neurological injury such as stroke or cardiac arrest. A good outcome will be defined as a mRS of 0 to 3 and a poor outcome as 4 to 6.

1 to 10 of 12Source ClinicalTrials.gov

See all 12 registered outcomes

Outcomes12

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Number of Participants With Return of Spontaneous Circulation	During the cardiac arrest, an average of 20 minutes	participants	NUMBER
SECONDARY	Number of Participants That Survived 30 Days	At 30 days	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Participants With a Favorable Neurological Outcome at 30 Days	At 30 days	Participants	COUNT_OF_PARTICIPANTS
OTHER_PRE_SPECIFIED	Vasopressor-free Days	7 days
OTHER_PRE_SPECIFIED	Invasive Ventilation-free Days	7 days
OTHER_PRE_SPECIFIED	Sequential Organ Failure Assessment (SOFA) Score at 24, 48 and 72 Hours	24, 48 and 72 hours
OTHER_PRE_SPECIFIED	Hospital Disposition	At hospital discharge, up to 1 year
OTHER_PRE_SPECIFIED	Survival	At 90 days, 180 days, and 1 year
OTHER_PRE_SPECIFIED	Favorable Neurological Outcome	At 90 days, 180 days, and 1 year
OTHER_PRE_SPECIFIED	Modified Rankin Scale (mRS)	At 30 days, 90 days, 180 days, and 1 year

1 to 10 of 12Source ClinicalTrials.gov

See all 12 outcomes

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Number of Participants With Return of Spontaneous Circulation	Vasopressin and Methylprednisolone	100	participants
Number of Participants With Return of Spontaneous Circulation	Placebo	86	participants
Number of Participants That Survived 30 Days	Vasopressin and Methylprednisolone	23	Participants
Number of Participants That Survived 30 Days	Placebo	31	Participants
Number of Participants With a Favorable Neurological Outcome at 30 Days	Vasopressin and Methylprednisolone	18	Participants
Number of Participants With a Favorable Neurological Outcome at 30 Days	Placebo	20	Participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Vasopressin and Methylprednisolone	237
Overall Study	STARTED	Placebo	264
Overall Study	COMPLETED	Vasopressin and Methylprednisolone	237
Overall Study	COMPLETED	Placebo	264
Overall Study	NOT COMPLETED	Vasopressin and Methylprednisolone	0
Overall Study	NOT COMPLETED	Placebo	0

Source ClinicalTrials.gov

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Vasopressin and Methylprednisolone	214	237
Total, all-cause mortality	Placebo	233	264
Total, other adverse events	Vasopressin and Methylprednisolone	0	237
Total, other adverse events	Placebo	0	264
Total, serious adverse events	Vasopressin and Methylprednisolone	0	237
Total, serious adverse events	Placebo	0	264

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
34223347	DERIVED	PubMed
34587236	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons5

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Vasopressin and Methylprednisolone vs Placebo: Number of Participants That Survived 30 Days	Trial comparisons
Vasopressin and Methylprednisolone vs Placebo: Number of Participants With Return of Spontaneous Circulation	Trial comparisons
Vasopressin and Methylprednisolone vs Placebo: Number of Participants With a Favorable Neurological Outcome at 30 Days	Trial comparisons
Vasopressin and Methylprednisolone vs Placebo: deaths from any cause	Trial comparisons
Vasopressin and Methylprednisolone vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03640949

GET https://conductscience.org/api/trials/v1/NCT03640949/registered

API reference For AI assistants